Zacks Investment Research upgraded shares of Uniqure (NASDAQ:QURE) from a hold rating to a buy rating in a research report report published on Tuesday, Zacks.com reports. Zacks Investment Research currently has $52.00 price target on the biotechnology company’s stock.
According to Zacks, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. “
A number of other analysts also recently issued reports on QURE. Chardan Capital reduced their price target on shares of Uniqure from $105.00 to $80.00 and set a buy rating on the stock in a report on Thursday, June 25th. Stifel Nicolaus lowered their target price on Uniqure from $86.00 to $78.00 and set a buy rating for the company in a research report on Thursday, June 25th. They noted that the move was a valuation call. Robert W. Baird cut shares of Uniqure from an outperform rating to a neutral rating and set a $58.00 price target on the stock. in a research report on Thursday, June 25th. Wells Fargo & Co downgraded shares of Uniqure from an overweight rating to an equal weight rating and decreased their price target for the company from $90.00 to $56.00 in a research note on Thursday, June 25th. Finally, ValuEngine cut shares of Uniqure from a strong-buy rating to a buy rating in a research note on Tuesday, April 14th. Five research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Uniqure currently has an average rating of Buy and a consensus price target of $74.00.
NASDAQ QURE opened at $45.73 on Tuesday. The stock’s 50-day moving average price is $61.36 and its 200-day moving average price is $59.87. The company has a quick ratio of 12.89, a current ratio of 12.89 and a debt-to-equity ratio of 0.12. Uniqure has a 52 week low of $36.20 and a 52 week high of $77.46. The company has a market capitalization of $2.03 billion, a P/E ratio of -15.19 and a beta of 1.29.
Uniqure (NASDAQ:QURE) last released its earnings results on Wednesday, April 29th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.84) by $0.21. Uniqure had a negative net margin of 1,991.17% and a negative return on equity of 45.23%. The company had revenue of $0.10 million during the quarter, compared to analyst estimates of $1.76 million. Research analysts anticipate that Uniqure will post -0.07 EPS for the current year.
In related news, CAO Christian Klemt sold 2,250 shares of the stock in a transaction that occurred on Friday, April 24th. The stock was sold at an average price of $60.00, for a total value of $135,000.00. Following the transaction, the chief accounting officer now owns 59,268 shares of the company’s stock, valued at $3,556,080. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Robert Gut sold 26,875 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $70.00, for a total value of $1,881,250.00. Over the last quarter, insiders have sold 46,002 shares of company stock valued at $3,044,829. Corporate insiders own 2.66% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Exane Asset Management purchased a new position in shares of Uniqure in the 4th quarter valued at approximately $717,000. Victory Capital Management Inc. increased its stake in Uniqure by 140.5% during the 4th quarter. Victory Capital Management Inc. now owns 6,128 shares of the biotechnology company’s stock valued at $353,000 after purchasing an additional 3,580 shares in the last quarter. New York State Common Retirement Fund raised its holdings in shares of Uniqure by 39.1% in the fourth quarter. New York State Common Retirement Fund now owns 8,425 shares of the biotechnology company’s stock worth $604,000 after buying an additional 2,369 shares during the last quarter. State Street Corp raised its holdings in shares of Uniqure by 21.1% in the fourth quarter. State Street Corp now owns 73,651 shares of the biotechnology company’s stock worth $5,278,000 after buying an additional 12,809 shares during the last quarter. Finally, Sei Investments Co. acquired a new stake in shares of Uniqure during the fourth quarter worth $1,199,000. 78.65% of the stock is currently owned by institutional investors and hedge funds.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Further Reading: What causes a yield curve to invert?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.